AbCellera acquires TetraGenetics

By The Science Advisory Board staff writers

September 13, 2021 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has acquired biotechnology firm TetraGenetics.

TetraGenetics offers a platform that generates recombinant human ion channels and transmembrane proteins such as G protein-coupled receptors. The acquisition will allow AbCellera to integrate TetraGenetics' biotechnology into its drug discovery efforts, it said.

Financial details of the acquisition were not disclosed.

Tachyon, AbCellera to develop novel cancer antibody therapeutic
Tachyon Therapeutics and antibody discovery company AbCellera are teaming up to develop a first-in-class therapeutic antibody targeting the secreted extracellular...
AbCellera, Empirico use advanced computation to discover novel antibodies
AbCellera has entered into a strategic, multitarget collaboration with Empirico to discover novel therapeutic antibodies.
AbCellera acquires Trianni for $90M
Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's...
AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity...
AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.

Copyright © 2021 scienceboard.net


Conferences
Bio-IT World Conference and Expo
September 20-22
Boston, Massachusetts United States
BioProcess International
September 20-23
Boston, Massachusetts United States
Cell and Gene Therapy Manufacturing and Commercialization
September 20-23
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter